What is DelSiTech?
DelSiTech is a technology platform company specializing in advanced long-acting formulations designed to revolutionize treatment paradigms for metabolic diseases and chronic pain. Leveraging its proprietary Silica Matrix technology, DelSiTech engineers biodegradable drug delivery systems that are compatible with a wide array of therapeutic agents. These systems are engineered to provide sustained release of medication, thereby enhancing patient adherence and reducing the frequency of dosing. The company actively pursues collaborations with biopharmaceutical and pharmaceutical partners to advance its innovative drug delivery solutions, aiming to significantly improve patient quality of life.
How much funding has DelSiTech raised?
DelSiTech has raised a total of $10.8M across 1 funding round:
Other Financing Round
$10.8M
Other Financing Round (2024): $10.8M with participation from DRW Venture Capital and Tolmar
Key Investors in DelSiTech
DRW Venture Capital
DRW Venture Capital is a firm that focuses on investing in early-stage technology companies, providing capital and strategic guidance to foster growth and success.
Tolmar
Tolmar Pharmaceuticals is a fully integrated pharmaceutical company focused on the development, manufacturing, and commercialization of specialty pharmaceuticals, particularly in Urology.
What's next for DelSiTech?
The recent major strategic investment signifies a pivotal moment for DelSiTech, likely enabling the company to accelerate the clinical development and commercialization of its proprietary drug delivery platforms. This capital infusion is expected to bolster research and development efforts, expand manufacturing capabilities, and potentially forge new strategic partnerships. DelSiTech's focus on long-acting formulations positions it to address unmet needs in chronic disease management, suggesting a future trajectory geared towards scaling operations and achieving broader market penetration in the biopharmaceutical sector.
See full DelSiTech company page
